• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将化疗引起的发热性中性粒细胞减少症发作分类为三种发热性中性粒细胞减少综合征之一。

Classification of Chemotherapy-Induced Febrile Neutropenic Episodes Into One of the Three Febrile Neutropenic Syndromes.

作者信息

Raheja Ronak, Reddy Neelesh, Patel Twinkle, Kilambi Srikar, Mathew Ashik A, Majeed Abdul

机构信息

Department of Internal Medicine, Kempegowda Institute of Medical Sciences, Bengaluru, IND.

Department of Medical Oncology, Columbia Asia Referral Hospital Yeshwanthpur, Bangalore, IND.

出版信息

Cureus. 2023 Aug 2;15(8):e42843. doi: 10.7759/cureus.42843. eCollection 2023 Aug.

DOI:10.7759/cureus.42843
PMID:37664262
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10472482/
Abstract

Introduction Febrile neutropenia is a commonly encountered medical emergency in patients undergoing cancer treatment and can delay and modify the course of treatment and even lead to dire outcomes, including death. The cause of fever in a post-chemotherapy-induced neutropenic patient can be confusing to treating physicians. A review of the literature demonstrated that blood culture results could determine the cause of febrile neutropenia in only approximately 10% to 25% of patients. The objective of our study was to measure the incidence of positive blood cultures, urine cultures, and other body fluid cultures resulting in chemotherapy-induced neutropenia and further classify fever episodes into three neutropenic fever syndromes, such as microbiologically documented, clinically suspected, or unknown causes of fever, respectively. Methods We conducted a prospective observational study on 399 chemotherapy-induced neutropenic fever episodes with the aim of classifying them into one of the three neutropenic syndromes. We tried to document the cause of the fever in these patients. We also noted the type of cancer treatment regimen they were on and correlated their clinical profile with their body fluid cultures, including blood cultures, urine cultures, and other body fluid cultures. We then categorized each fever episode into one of three neutropenic syndromes. Results We studied 399 febrile neutropenic episodes. We were able to microbiologically document the cause of fever in 39% of the cases, and we obtained growth in 51 out of 399 blood cultures (13%), which was comparable to the available literature, and urine culture showed growth in 62 out of 399 cultures (16%), while other body cultures such as pus culture, bile culture, and bronchioalveolar lavage cultures collectively showed growth in 42 out of 399 episodes (10%). The most common bacteria isolated in both blood and urine cultures were . Cumulatively, including blood, urine, and body fluid cultures, we were able to classify 39% (155 out of 399 cases) of febrile neutropenic episodes as microbiologically documented. The cause of fever was clinically suspected by means of careful history taking and an extensive physical examination in 31% (125 out of 399) without growth evidence in blood cultures, urine cultures, or any other body fluid culture. The cause of fever remained unknown in 119 cases (30%) of patients and was classified under the unknown cause of fever. Conclusions We conclude by stating that the study of fever in a neutropenic patient should include a thorough history and clinical evaluation of blood, urine, and other body fluid cultures instead of solely relying on blood culture results. We recommend further classifying patients into one of the three neutropenic fever syndromes, such as those that are microbiologically documented, clinically suspected, or unknown. Our blood cultures were able to give us a 13% positivity rate, whereas microbiologically, we were able to isolate an organism likely causing fever in 39% of patients. The cause of fever was suspected clinically in 31% of patients, but we were unsuccessful in microbiologically documenting any culture growth in blood, urine, or any other body fluid culture. The cause of fever remained a mystery and unknown to us without any microbiological or clinical cues in 119 cases (30%) of febrile neutropenic episodes.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/e1134456fe07/cureus-0015-00000042843-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/82f1d63d9249/cureus-0015-00000042843-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/8ad5511820db/cureus-0015-00000042843-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/1a27d050dec9/cureus-0015-00000042843-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/563fb7068aa9/cureus-0015-00000042843-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/e1134456fe07/cureus-0015-00000042843-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/82f1d63d9249/cureus-0015-00000042843-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/8ad5511820db/cureus-0015-00000042843-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/1a27d050dec9/cureus-0015-00000042843-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/563fb7068aa9/cureus-0015-00000042843-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a7e/10472482/e1134456fe07/cureus-0015-00000042843-i05.jpg
摘要

引言 发热性中性粒细胞减少是癌症治疗患者中常见的医疗急症,可延误和改变治疗进程,甚至导致严重后果,包括死亡。化疗后出现中性粒细胞减少的患者发热原因可能会让治疗医生感到困惑。文献综述表明,血培养结果仅能确定约10%至25%的发热性中性粒细胞减少患者的病因。我们研究的目的是测定导致化疗引起的中性粒细胞减少的血培养、尿培养及其他体液培养阳性的发生率,并将发热发作进一步分为三种中性粒细胞减少发热综合征,分别为微生物学确诊、临床怀疑或不明原因发热。

方法 我们对399例化疗引起的中性粒细胞减少发热发作进行了前瞻性观察研究,目的是将其分类为三种中性粒细胞减少综合征之一。我们试图记录这些患者的发热原因。我们还记录了他们所接受的癌症治疗方案类型,并将他们的临床特征与包括血培养、尿培养及其他体液培养在内的体液培养结果相关联。然后我们将每个发热发作分类为三种中性粒细胞减少综合征之一。

结果 我们研究了399例发热性中性粒细胞减少发作。我们能够在39%的病例中通过微生物学确定发热原因,399份血培养中有51份(13%)培养出细菌,这与现有文献相当,399份尿培养中有62份(16%)培养出细菌,而其他体液培养如脓液培养、胆汁培养和支气管肺泡灌洗培养在399次发作中共42份(10%)培养出细菌。血培养和尿培养中分离出的最常见细菌是……累计起来,包括血、尿和体液培养,我们能够将39%(399例中的155例)的发热性中性粒细胞减少发作分类为微生物学确诊。通过仔细询问病史和全面体格检查,在31%(399例中的125例)血培养、尿培养或任何其他体液培养无细菌生长证据的病例中临床怀疑发热原因。119例(30%)患者的发热原因仍不清楚,归类为不明原因发热。

结论 我们的结论是,对中性粒细胞减少患者发热的研究应包括对血、尿和其他体液培养进行全面的病史询问和临床评估,而不是仅依赖血培养结果。我们建议将患者进一步分类为三种中性粒细胞减少发热综合征之一,即微生物学确诊、临床怀疑或不明原因。我们的血培养阳性率为13%,而从微生物学角度,我们能够在39%的患者中分离出可能导致发热的病原体。31%的患者临床怀疑发热原因,但我们未能在血、尿或任何其他体液培养中通过微生物学记录到任何细菌生长。在119例(30%)发热性中性粒细胞减少发作中,发热原因在没有任何微生物学或临床线索的情况下仍然是个谜,我们对此并不清楚。

相似文献

1
Classification of Chemotherapy-Induced Febrile Neutropenic Episodes Into One of the Three Febrile Neutropenic Syndromes.将化疗引起的发热性中性粒细胞减少症发作分类为三种发热性中性粒细胞减少综合征之一。
Cureus. 2023 Aug 2;15(8):e42843. doi: 10.7759/cureus.42843. eCollection 2023 Aug.
2
Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients.小儿血液肿瘤患者发热性中性粒细胞减少发作的评估。
Turk Pediatri Ars. 2017 Dec 1;52(4):213-220. doi: 10.5152/TurkPediatriArs.2017.5312. eCollection 2017 Dec.
3
Causative pathogens of fever in neutropenic patients at King Chulalongkorn Memorial Hospital.朱拉隆功国王纪念医院中性粒细胞减少患者发热的致病病原体
J Med Assoc Thai. 2010 Jul;93(7):776-83.
4
Evaluation of predictors of adverse outcome in febrile neutropenic episodes in pediatric oncology patients.评估儿科肿瘤患者中性粒细胞减少性发热中不良结局的预测因素。
Indian J Pediatr. 2013 Apr;80(4):297-302. doi: 10.1007/s12098-012-0925-3. Epub 2012 Dec 21.
5
Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia.多重血液 PCR 联合血液培养在发热性中性粒细胞减少症中改善感染的微生物学记录。
J Clin Microbiol. 2010 Oct;48(10):3510-6. doi: 10.1128/JCM.00147-10. Epub 2010 Aug 18.
6
Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients.骨髓移植受者中的细胞壁缺陷型细菌与培养阴性发热性发作
Lancet. 2001 Mar 3;357(9257):675-9. doi: 10.1016/S0140-6736(00)04131-3.
7
Surveillance Stool Culture and its Association with Microbiologically Documented Infection During Febrile Neutropenia in Patients with Acute Leukemia (AL) Undergoing Induction Chemotherapy.急性白血病(AL)患者诱导化疗期间发热性中性粒细胞减少症的监测粪便培养及其与微生物学确诊感染的关联
Indian J Hematol Blood Transfus. 2021 Oct;37(4):543-548. doi: 10.1007/s12288-020-01377-7. Epub 2020 Nov 9.
8
[Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination].[哌拉西林-他唑巴坦与奈替米星联合治疗儿童发热性中性粒细胞减少症发作]
Med Mal Infect. 2005 Jun;35(6):357-62. doi: 10.1016/j.medmal.2005.04.004.
9
Aztreonam and Vancomycin for Initial Treatment of Febrile Neutropenia in Penicillin-Allergic Patients During Hematopoietic Stem Cell Transplantation.氨曲南和万古霉素用于造血干细胞移植期间青霉素过敏患者发热性中性粒细胞减少症的初始治疗。
J Adv Pract Oncol. 2019 Sep-Oct;10(7):685-690. doi: 10.6004/jadpro.2019.10.7.4. Epub 2019 Sep 1.
10
Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes.与严重脓毒症相关的因素:对94例中性粒细胞减少伴发热发作的前瞻性研究。
Hematology. 2010 Feb;15(1):28-32. doi: 10.1179/102453310X12583347009577.

引用本文的文献

1
Individualized Treatment Approach for Rectal Adenocarcinoma in the Setting of Congenital Neutropenia.先天性中性粒细胞减少症背景下直肠腺癌的个体化治疗方法
Cureus. 2024 Mar 18;16(3):e56383. doi: 10.7759/cureus.56383. eCollection 2024 Mar.

本文引用的文献

1
Culture-negative sepsis.阴性菌血症。
Curr Opin Crit Care. 2020 Oct;26(5):473-477. doi: 10.1097/MCC.0000000000000751.
2
Approach to Positive Blood Cultures in the Hospitalized Patient: A Review.住院患者血培养阳性的处理方法:综述
Mo Med. 2019 Jul-Aug;116(4):313-317.
3
Culture-Negative and Culture-Positive Sepsis: A Comparison of Characteristics and Outcomes.文化阴性和文化阳性脓毒症:特征和结局比较。
Anesth Analg. 2019 Nov;129(5):1300-1309. doi: 10.1213/ANE.0000000000004072.
4
Epidemiology and Immune Pathogenesis of Viral Sepsis.病毒败血症的流行病学和免疫发病机制。
Front Immunol. 2018 Sep 27;9:2147. doi: 10.3389/fimmu.2018.02147. eCollection 2018.
5
SIRS, qSOFA and new sepsis definition.全身炎症反应综合征、快速序贯器官功能衰竭评分及新的脓毒症定义。
J Thorac Dis. 2017 Apr;9(4):943-945. doi: 10.21037/jtd.2017.03.125.
6
Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: A timeline of clinical and microbial trends through the years.印度南部一家三级癌症研究所发热性中性粒细胞减少患者的血流感染:多年来临床和微生物趋势的时间线。
Indian J Med Paediatr Oncol. 2016 Jul-Sep;37(3):174-82. doi: 10.4103/0971-5851.190352.
7
When to Use Prophylactic Antibiotics in Neutropenic Patients.中性粒细胞减少患者何时使用预防性抗生素
Oncology (Williston Park). 2016 Sep 15;30(9):838-40, 846.
8
Bloodstream infections in neutropenic cancer patients: A practical update.中性粒细胞减少症癌症患者血流感染:实用更新。
Virulence. 2016 Apr 2;7(3):280-97. doi: 10.1080/21505594.2016.1156821.
9
Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.血液系统恶性肿瘤中发热性中性粒细胞减少症的治疗与预防:一项批判性综述与更新
Adv Hematol. 2014;2014:986938. doi: 10.1155/2014/986938. Epub 2014 Nov 27.
10
Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).中性粒细胞减少患者脓毒症的管理:德国血液学和医学肿瘤学会传染病工作组(AGIHO)2014年更新指南
Ann Hematol. 2014 Jul;93(7):1083-95. doi: 10.1007/s00277-014-2086-0. Epub 2014 Apr 29.